Kodiak Sciences announced positive Phase 3 trial results for its three late-stage retinal drug candidates, including Zenkuda and Tabirafusp-ted, showing efficacy in wet AMD and diabetic macular edema. The company plans to submit a biologics license application (BLA) for Zenkuda by the end of 2026 and expects topline data for KSI-101 in December 2026, with a BLA filing planned for mid-2027. Kodiak raised $69 million post-Q3 2026 and ended the quarter with $88.7 million in cash, supporting operations into 2027. These developments position Kodiak to potentially offer new treatment options for major retinal diseases.
Kodiak Sciences' recent business highlights and Q3 2026 results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced health-sector US stocks, only 23 rose while 124 fell. Among notable movers, CTXR gained 11.19% to USD 0.53 with mostly sell orders (84%), contrasting with SMMT and IBRX, which dropped 9.25% and 9.15% to USD 15.10 and USD 6.06 respectively, with SMMT seeing more buy orders (57%) and IBRX predominantly sell orders (98%).
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
